Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

Posted on by

The Lancet
Feb 05, 2022 Volume 399 Number 10324 p495-604, e3-e5
https://www.thelancet.com/journals/lancet/issue/current

 

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
The ITAC (INSIGHT 013) Study Group